Hossein Borghaei, MD discusses lurbinectedin recent data and advantages and potential limitations of the new drug

PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Hossein Borghaei, MD discusses the recent data released and advantages and potential lim... Author: PharmaMar Added: 08/21/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts